Can I have your opinion on NBLY results released today?
EPS of $0.06 missed estimates of $0.067 and revenues of $190.612M missed estimates of $191.117M. Sales increased substantially for the quarter, largely due to pharmacies acquired over the past year. Its same-store sales saw growth of 1.6%, and its Adjusted EBITDA margin grew slightly from 10.1% in the prior year to 10.3%. The company continues to expand its network of pharmacies and both its balance sheet and cash flow have shown tremendous improvement over the past year. NBLY continues to operate at a loss but it is expecting to be profitable within the year or more and given its high growth rates, its valuation of 21.8X forward P/E is fairly reasonable. We feel that in a better market backdrop, NBLY's high growth rates and network expansion can be rewarded.